Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.
Document Type
Journal Article
Publication Date
3-22-2018
Journal
Genetics in medicine : official journal of the American College of Medical Genetics
DOI
10.1038/gim.2018.2
APA Citation
Hahn, S., Kronn, D., Leslie, N., Pena, L., Tanpaiboon, P., Gambello, M., Gibson, J., Hillman, R., Stockton, D., Day, J., Wang, R., An Haack, K., Shafi, R., Sparks, S., Zhao, Y., Wilson, C., & Kishnani, P. (2018). Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.. Genetics in medicine : official journal of the American College of Medical Genetics, (). http://dx.doi.org/10.1038/gim.2018.2
Peer Reviewed
1
